Although vestibular schwannomas are common, benign intracranial tumors with similar histopathology originating from other nerves are rare. For non-vestibular schwannomas, surgery remains standard treatment, albeit associated with morbidities. Radiotherapy offers a safe and effective alternative treatment modality....
No actionable change for audiologists; treatment decisions for non-vestibular schwannomas fall within neurosurgery and radiation oncology, though audiologists monitoring these patients should be aware of evolving radiotherapy schedules and their potential hearing-related sequelae.
Schwannomas can affect hearing and cranial nerve function; clarifying optimal radiotherapy fractionation helps guide neuro-oncology teams and informs audiological monitoring protocols for affected patients.
- 01Retrospective cohort study from Ramathibodi Hospital, Thailand.
- 02Compared hypo-fractionated vs. conventional fractionated stereotactic radiotherapy for non-vestibular schwannomas.
- 03Non-vestibular schwannomas arise from cranial nerves other than CN VIII (the hearing/balance nerve).
- 04Long-term tumour control and toxicity outcomes were assessed.
- 05Retrospective design limits causal inference; findings are hypothesis-generating.
Hypo-fractionated stereotactic radiotherapy produces long-term outcomes comparable to conventional fractionation for non-vestibular schwannomas.
studypartially supported- PMID
- 42289335
- DOI
- 10.2176/jns-nmc.2026-0067.
- Journal
- Neurologia Medico-Chirurgica
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Patients with non-vestibular schwannomas treated at Ramathibodi Hospital
- Intervention
- Hypo-fractionated stereotactic radiotherapy
- Comparator
- Conventional fractionated stereotactic radiotherapy
Primary outcomes
Long-term tumour control rates; Treatment-related toxicity and adverse outcomes